Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model

Sendegul Yildirim1, Ayse Ozkan2, Gunes Aytac3

  • 1Akdeniz University, Faculty of Medicine, Department of Histology and Embryology, Antalya, Turkey.

Neurotoxicology
|November 22, 2021
PubMed

Insights

Melatonin treatment reduced alpha-synuclein aggregation and toll-like receptor 4 (TLR4)-mediated inflammation in a mouse model of Parkinson's disease (PD). This neuroprotective effect improved motor activity and preserved dopaminergic neurons.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Immunology

Background:

  • Neuroinflammation, particularly microglial activation, plays a critical role in neurodegenerative diseases like Parkinson's disease (PD).
  • Toll-like receptor 4 (TLR4) activation in glial cells triggers inflammatory cytokine release via NF-kB, leading to dopaminergic neuron death.
  • The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model is used to study PD pathogenesis, involving alpha-synuclein accumulation and dopaminergic neuron loss.

Purpose of the Study:

  • To investigate the potential of melatonin to suppress TLR4-mediated neuroinflammation in the MPTP-induced mouse model of PD.
  • To assess melatonin's effect on cytokine release, alpha-synuclein accumulation, and dopaminergic neuron survival.
  • To evaluate the impact of melatonin on motor deficits in the MPTP-induced PD model.

Main Methods:

  • MPTP toxin was administered to induce Parkinson's-like pathology in C57BL/6 mice.
  • Melatonin was administered intraperitoneally to assess its therapeutic effects.
  • Locomotor activity, tyrosine hydroxylase (TH) immunohistochemistry, TLR4, alpha-synuclein, p65, and TNF-alpha expression were evaluated.

Main Results:

  • MPTP injection significantly impaired locomotor activity and reduced TH expression in dopaminergic neurons.
  • Melatonin administration improved motor function and preserved dopaminergic neurons.
  • Melatonin treatment significantly decreased the expression of TLR4, alpha-synuclein, p65, and TNF-alpha in MPTP-treated mice.

Conclusions:

  • Melatonin effectively suppresses TLR4-mediated neuroinflammation and alpha-synuclein aggregation in the MPTP-induced mouse model.
  • Melatonin demonstrates neuroprotective properties, mitigating dopaminergic neuron loss and improving motor deficits.
  • Melatonin holds promise as a therapeutic agent for Parkinson's disease by targeting key inflammatory pathways.

Related Concept Videos